Free Trial

CVS Medicare Advantage business takes quality rating hit

CVS sign is shown in Wadsworth Plaza in Philadelphia, Wednesday, Sept. 29, 2021. CVS Health shares tumbled early Friday, Oct. 7, 2022, after the company said a big Medicare Advantage plan took a hit in government quality ratings about a week before a key enrollment window opens for the coverage. (AP Photo/Matt Rourke)

CVS Health shares tumbled early Friday after the company said a big Medicare Advantage plan took a hit in government quality ratings about a week before a key enrollment window opens for the coverage.

The health care giant said that its Aetna National PPO dropped from 4.5 stars to 3.5 in 2023 ratings, which were released Thursday by the Centers for Medicare and Medicaid Services.

Plans are rated on a scale of 1 to 5, with five representing excellent, according to CMS. The ratings are released annually and reflect the experiences of people enrolled in the plan.

The drop means the plan will no longer be eligible for a CMS quality bonus payment. It also could affect enrollment, since some shoppers factor the ratings into their coverage decision.

The Aetna plan covers all 50 states with nearly 2 million people enrolled, which is more than half of Aetna’s total Medicare Advantage enrollment. Aetna is the health insurance division of CVS Health, which also runs a national drugstore chain and manages prescription drug coverage.

CVS Health said the main reason for the rating drop was a scoring system based on survey results from 976 customers, or well under 1% of the plan’s enrollment.

Medicare Advantage plans are privately run versions of the government’s Medicare program for people who are age 65 and older or have certain disabilities. The annual enrollment window for 2023 plans opens Oct. 15 and runs until Dec. 7.

Shares of CVS Health Corp., which is based in Woonsocket, Rhode Island, were down 4.7%, or $4.65, to $93.93 before markets opened Friday.

→ Central Bank Abandons USD (From True Gold Republic) (Ad)

Should you invest $1,000 in CVS Health right now?

Before you consider CVS Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.

While CVS Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Aetna (AET)N/A$212.70flat0.94%21.57N/AN/A
CVS Health (CVS)
5 of 5 stars
$55.11+1.5%4.83%13.99Moderate Buy$73.00
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Recent Videos

Why SoundHound Stock Dip Could Mean Big Gains for 2025 Investors
Nintendo Stock: Buy Before the 2025 Switch Platform Hits!
How to Profit from NVIDIA’s Earnings: Short-Term Trading Guide

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines